About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Cdkn2atm2.1Rdp
targeted mutation 2.1, Ronald DePinho
MGI:2384177
Summary 14 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp involves: 129S6/SvEvTac * FVB/N MGI:3814389
ht2
Cdkn2atm2.1Rdp/Cdkn2a+ involves: 129S6/SvEvTac * FVB/N MGI:3814390
cn3
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N MGI:5308962
cn4
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N MGI:5308954
cn5
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N MGI:5308961
cn6
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N MGI:5308963
cn7
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N MGI:5308951
cn8
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N MGI:5659885
cn9
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N MGI:5659896
cn10
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N MGI:5502381
cx11
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Nf1tm1Tyj/Nf1+
involves: 129S2/SvPas * 129S6/SvEvTac MGI:3776068
cx12
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Tg(GFAP-TVA)5Hev/0
involves: 129S6/SvEvTac * BALB/c * C57BL/6 * FVB/N MGI:3835352
cx13
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Tg(NES-TVA)J12Ech/0
involves: 129S6/SvEvTac * C57BL/6 * FVB/N MGI:3835366
cx14
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
X/Tg(Tyr-HRAS)60Lc
involves: 129S6/SvEvTac * C57BL/6J * CBA/J * FVB MGI:2676124


Genotype
MGI:3814389
hm1
Allelic
Composition
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Genetic
Background
involves: 129S6/SvEvTac * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm2.1Rdp mutation (2 available); any Cdkn2a mutation (57 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
skeleton
• 18% of spontaneous tumors that form in mutants are osteosarcomas

neoplasm
• between 28 and 58 weeks, 10 out of 39 mice develop tumors unlike wild-type mice (J:71394)
• increase in spontaneous and carcinogen-induced tumor incidence, but less than in Cdkn2atm1Rdp mice (J:88365)
• 12% and 5% of spontaneous and DMBA-induced tumors, respectively, that form in mutants are melanomas (J:88365)
• following treatment with DMBA, 50% of mice develop tumors by week 23 compared to later than week 35 for similarly treated wild-type mice (J:71394)
• following treatment with DMBA, mice develop lung adenomas that are more aggressive than in similarly treated wild-type mice (J:71394)
• following treatment with DMBA, mice exhibit an increase in spindle-cell neoplasms compared to in similarly treated wild-type mice (J:71394)
• treatment of mice with urethane results in a 4-fold increase in the number of lung adenomas compared to in similarly treated wild-type mice (J:71394)
• 18% of spontaneous tumors that form in mutants are histiocytic lymphomas
• spontaneous lymphocytic lymphomas are not observed in mutants, however 40% of DMBA-induced tumors are small lymphocytic lymphomas
• 29% of spontaneous tumors that form in mutants are malignant spindle cell neoplasms, most likely soft tissue sarcomas
• 23% of spontaneous tumors that form are angiosarcomas
• 30% of DMBA-induced tumors are malignant spindle cell neoplasms
• 18% of spontaneous tumors that form in mutants are osteosarcomas

immune system
• unsorted splenocytes exhibit increased proliferation compared to wild-type cells when stimulated with CD3 and CD28 but not LPS or IgM with CD40
• the thymus exhibits increased cortical thickness and cellularity
• mice exhibit a marked increased in the double positive compartment

homeostasis/metabolism
• following treatment with DMBA, 50% of mice develop tumors by week 23 compared to later than week 35 for similarly treated wild-type mice (J:71394)
• following treatment with DMBA, mice develop lung adenomas that are more aggressive than in similarly treated wild-type mice (J:71394)
• following treatment with DMBA, mice exhibit an increase in spindle-cell neoplasms compared to in similarly treated wild-type mice (J:71394)
• treatment of mice with urethane results in a 4-fold increase in the number of lung adenomas compared to in similarly treated wild-type mice (J:71394)

hematopoietic system
• unsorted splenocytes exhibit increased proliferation compared to wild-type cells when stimulated with CD3 and CD28 but not LPS or IgM with CD40
• the thymus exhibits increased cortical thickness and cellularity
• mice exhibit a marked increased in the double positive compartment

cellular
• unsorted splenocytes exhibit increased proliferation compared to wild-type cells when stimulated with CD3 and CD28 but not LPS or IgM with CD40

endocrine/exocrine glands
• the thymus exhibits increased cortical thickness and cellularity




Genotype
MGI:3814390
ht2
Allelic
Composition
Cdkn2atm2.1Rdp/Cdkn2a+
Genetic
Background
involves: 129S6/SvEvTac * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm2.1Rdp mutation (2 available); any Cdkn2a mutation (57 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• between 28 and 58 weeks, 4 out of 60 mice develop tumors unlike wild-type mice




Genotype
MGI:5308962
cn3
Allelic
Composition
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
Genetic
Background
involves: 129 * C57BL/6 * CBA * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm2.1Rdp mutation (2 available); any Cdkn2a mutation (57 available)
Krastm4Tyj mutation (9 available); any Kras mutation (55 available)
Tg(Pdx1-cre)89.1Dam mutation (2 available)
Trp53tm1Brn mutation (17 available); any Trp53 mutation (205 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• mutants develop pancreatic tumors with an average latency of 13.1 weeks
• 25% of tumors exhibit sarcomatoid carcinoma histology
• 75% of tumors exhibit well differentiated ductal adenocarcinoma histology

neoplasm
• mutants develop pancreatic tumors with an average latency of 13.1 weeks
• 25% of tumors exhibit sarcomatoid carcinoma histology
• 75% of tumors exhibit well differentiated ductal adenocarcinoma histology
• 25% of tumors exhibit metastasis

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
pancreatic ductal adenocarcinoma DOID:3498 J:108298




Genotype
MGI:5308954
cn4
Allelic
Composition
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
Genetic
Background
involves: 129 * C57BL/6 * CBA * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm2.1Rdp mutation (2 available); any Cdkn2a mutation (57 available)
Krastm4Tyj mutation (9 available); any Kras mutation (55 available)
Tg(Pdx1-cre)89.1Dam mutation (2 available)
Trp53tm1Brn mutation (17 available); any Trp53 mutation (205 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• mutants develop pancreatic tumors with an average latency of 7.2 weeks
• 60% of tumors exhibit anaplastic carcinoma histology
• 40% of tumors exhibit well differentiated ductal adenocarcinoma histology

neoplasm
• mutants develop pancreatic tumors with an average latency of 7.2 weeks
• 60% of tumors exhibit anaplastic carcinoma histology
• 40% of tumors exhibit well differentiated ductal adenocarcinoma histology
• 20% of tumors exhibit metastasis

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
pancreatic ductal adenocarcinoma DOID:3498 J:108298




Genotype
MGI:5308961
cn5
Allelic
Composition
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
Genetic
Background
involves: 129 * C57BL/6 * CBA * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm2.1Rdp mutation (2 available); any Cdkn2a mutation (57 available)
Krastm4Tyj mutation (9 available); any Kras mutation (55 available)
Tg(Pdx1-cre)89.1Dam mutation (2 available)
Trp53tm1Brn mutation (17 available); any Trp53 mutation (205 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• mutants develop pancreatic tumors with an average latency of 14.7 weeks
• 19% of tumors exhibit sarcomatoid differentiation
• 81% of tumors exhibit well differentiated ductal adenocarcinoma histology

neoplasm
• mutants develop pancreatic tumors with an average latency of 14.7 weeks
• 19% of tumors exhibit sarcomatoid differentiation
• 81% of tumors exhibit well differentiated ductal adenocarcinoma histology
• 25% of tumors exhibit metastasis




Genotype
MGI:5308963
cn6
Allelic
Composition
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0
Genetic
Background
involves: 129 * C57BL/6 * CBA * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm2.1Rdp mutation (2 available); any Cdkn2a mutation (57 available)
Krastm4Tyj mutation (9 available); any Kras mutation (55 available)
Tg(Pdx1-cre)89.1Dam mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• mutants develop pancreatic tumors with an average latency of 18.3 weeks
• 100% of tumors are sarcomatoid in histology

neoplasm
• mutants develop pancreatic tumors with an average latency of 18.3 weeks
• 100% of tumors are sarcomatoid in histology
• 33% of tumors exhibit metastasis




Genotype
MGI:5308951
cn7
Allelic
Composition
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
Genetic
Background
involves: 129 * C57BL/6 * CBA * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm2.1Rdp mutation (2 available); any Cdkn2a mutation (57 available)
Krastm4Tyj mutation (9 available); any Kras mutation (55 available)
Tg(Pdx1-cre)89.1Dam mutation (2 available)
Trp53tm1Brn mutation (17 available); any Trp53 mutation (205 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• mutants develop pancreatic tumors with an average latency of 6.5 weeks
• 20% of tumors exhibit anaplastic carcinoma histology
• 80% of tumors exhibit well differentiated ductal adenocarcinoma histology

neoplasm
• mutants develop pancreatic tumors with an average latency of 6.5 weeks
• 20% of tumors exhibit anaplastic carcinoma histology
• 80% of tumors exhibit well differentiated ductal adenocarcinoma histology

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
pancreatic ductal adenocarcinoma DOID:3498 J:108298




Genotype
MGI:5659885
cn8
Allelic
Composition
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Trp53tm1Brn/Trp53tm1Brn
Genetic
Background
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm2.1Rdp mutation (2 available); any Cdkn2a mutation (57 available)
Trp53tm1Brn mutation (17 available); any Trp53 mutation (205 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice inoculated with an adenovirus expressing cre recombinase (ad-cre) by inhalation have a median survival of 29 weeks after ad-cre inoculation

cardiovascular system
• mice inoculated with ad-cre exhibit a high frequency of fatal pulmonary hemorrhage

respiratory system
• mice inoculated with ad-cre exhibit a high frequency of fatal pulmonary hemorrhage
• some ad-cre inoculated mice develop lung tumors with low tumor multiplicity

neoplasm
• some ad-cre inoculated mice develop lung tumors with low tumor multiplicity




Genotype
MGI:5659896
cn9
Allelic
Composition
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Genetic
Background
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm2.1Rdp mutation (2 available); any Cdkn2a mutation (57 available)
Krastm4Tyj mutation (9 available); any Kras mutation (55 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• mice inoculated with ad-cre by inhalation develop infrequent highly lethal tumors; all tumors are adenocarcinomas

mortality/aging
• mice inoculated with an adenovirus expressing cre recombinase (ad-cre) by inhalation have a median survival of 24 weeks after ad-cre inoculation

neoplasm
• 3 of 15 (20%) ad-cre inoculated mice exhibit metastasis
• mice inoculated with ad-cre by inhalation develop infrequent highly lethal tumors; all tumors are adenocarcinomas




Genotype
MGI:5502381
cn10
Allelic
Composition
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Genetic
Background
involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm2.1Rdp mutation (2 available); any Cdkn2a mutation (57 available)
Krastm4Tyj mutation (9 available); any Kras mutation (55 available)
Tg(Pdx1-cre)6Tuv mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• starting between 6 and 24 weeks with metastasis
• adenocarcinomas in 21 of 22 invasive carcinomas in the pancreas

mortality/aging
• median survival 15.5 weeks

neoplasm
• starting between 6 and 24 weeks with metastasis
• adenocarcinomas in 21 of 22 invasive carcinomas in the pancreas
• adenocarcinomas in 21 of 22 invasive carcinomas in the pancreas

growth/size/body
• starting between 6 and 24 weeks
• increased girth starting between 6 and 24 weeks

liver/biliary system
• starting between 6 and 24 weeks

homeostasis/metabolism
• starting between 6 and 24 weeks




Genotype
MGI:3776068
cx11
Allelic
Composition
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Nf1tm1Tyj/Nf1+
Genetic
Background
involves: 129S2/SvPas * 129S6/SvEvTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm2.1Rdp mutation (2 available); any Cdkn2a mutation (57 available)
Nf1tm1Tyj mutation (3 available); any Nf1 mutation (111 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
N
• unlike other mice with at least one Nf1tm1Tyj allele, mice do not display malignant peripheral nerve sheath tumors or neurofibromas
• hematopoietic neoplasms, especially lymphoma, are seen in some mice




Genotype
MGI:3835352
cx12
Allelic
Composition
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Tg(GFAP-TVA)5Hev/0
Genetic
Background
involves: 129S6/SvEvTac * BALB/c * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm2.1Rdp mutation (2 available); any Cdkn2a mutation (57 available)
Tg(GFAP-TVA)5Hev mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• 23 gliomas are discovered in 28 mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB
• 18 grade II (similar to human oligodendroglioma) and 5 grade III (similar to anaplastic oligodendroglioma)

mortality/aging
• after 84 days, mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB exhibit 25% compared to 85% survival in similarly treated Tg(GFAP-TVA)5Hev mice

neoplasm
• 23 gliomas are discovered in 28 mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB
• 18 grade II (similar to human oligodendroglioma) and 5 grade III (similar to anaplastic oligodendroglioma)




Genotype
MGI:3835366
cx13
Allelic
Composition
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Tg(NES-TVA)J12Ech/0
Genetic
Background
involves: 129S6/SvEvTac * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm2.1Rdp mutation (2 available); any Cdkn2a mutation (57 available)
Tg(NES-TVA)J12Ech mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• 22 gliomas are discovered in 28 mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB
• 21 grade II (similar to human oligodendroglioma) and 1 grade III (similar to anaplastic oligodendroglioma)

mortality/aging
• after 84 days, mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB exhibit 20% compared to 50% survival in similarly treated Tg(NES-TVA)12Hev mice

neoplasm
• 22 gliomas are discovered in 28 mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB
• 21 grade II (similar to human oligodendroglioma) and 1 grade III (similar to anaplastic oligodendroglioma)




Genotype
MGI:2676124
cx14
Allelic
Composition
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
X/Tg(Tyr-HRAS)60Lc
Genetic
Background
involves: 129S6/SvEvTac * C57BL/6J * CBA/J * FVB
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm2.1Rdp mutation (2 available); any Cdkn2a mutation (57 available)
Tg(Tyr-HRAS)60Lc mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• 75 week melanoma free survival as opposed to 89 weeks for wild-type mice
• functioning of p19ARF was compromised in more than half of the tumors examined
• about 40% of tumors overexpressed p53 as demonstrated by Western blot analysis





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
01/18/2022
MGI 6.17
The Jackson Laboratory